Last reviewed · How we verify
NCT03808194
Lotto to Link Study: A Prospective, Interventional, Randomized Study of Conditional Incentives
NA trial testing Conditional lottery incentive in Incentives in 132 participants. Completed in 31 January 2019.
30 November 2018
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 132 |
| Start date | 26 October 2017 |
| Primary completion | 30 November 2018 |
| Estimated completion | 31 January 2019 |
| Sites | 1 location across South Africa |
Drugs / interventions tested
- Conditional lottery incentive
- Optimized ART linkage package
Conditions studied
- Incentives — all drugs for Incentives →
- HIV Infections — all drugs for HIV Infections →
- ART — all drugs for ART →
Sponsor
University of Washington
Who can join
18 and older, male only, with Incentives or HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study the investigators will adapt and strengthen, test effectiveness, and explore implementation of conditional lottery incentive linkage strategies to engage men in HIV care and ART in KwaZulu-Natal, South Africa.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lottery incentives have short-term impact on ART initiation among men: results from a randomized pilot study.
Barnabas RV, van Heerden A, McConnell M, Szpiro AA, et al · · 2020 · cited 27× · PMID 32589342 · DOI 10.1002/jia2.25519
Verify or expand the search:
- PubMed search for NCT03808194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Incentives
Currently open trials in the same condition.
- NCT06676787 — Evaluating the Impact of Demand-Side Incentives (DSI) on Zero Dose Burden and Immunisation Coverage in Nigeria · EARLY_PHASE1 · recruiting
- NCT06340841 — LEMURS SSI: Evaluation of Behavioral Incentives · Phase 1 · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03808194 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 30 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03808194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing